

Special Issue

Multi-Omics Dissection of EMT-Driven Cancer Metabolism in Drug Resistance and Metastasis

Message from the Guest Editor

This Special Issue will uncover critical metabolic adaptations driving cancer progression, with special emphasis on the Epithelial-to-Mesenchymal Transition (EMT), drug resistance, and metastatic capacity. By leveraging a multi-omics framework, which integrates genomics, transcriptomics, proteomics, and metabolomics, it seeks to comprehensively map the metabolic shifts that enable tumor cells to transition to more invasive phenotypes and evade standard therapies.

Guest Editor

Dr. Lei Huang

Department of Molecular Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA

Deadline for manuscript submissions

20 September 2025



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/228685

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).